MIF-2
Companion compound to MIF-1 in grey-market myostatin-inhibitor branding — same minimal research base, same naming overlap with older unrelated literature.
Investigational compounds — read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
MIF-2 is a short peptide marketed alongside MIF-1 in performance-enhancement channels under myostatin-inhibitor branding. Like MIF-1, the contemporary marketing claims substantially outrun the underlying published myostatin-biology research base.
- Class
- Synthetic short peptide
- Sponsor
- None
- Stage
- Preclinical / theoretical
- Marketed claim
- Myostatin inhibition
What it is
MIF-2 (sometimes written MIF2) is a short peptide marketed in grey-market peptide channels as a companion myostatin inhibitor to MIF-1. The original literature on the MIF-2 designation (Pro-Leu-Gly-NH2 in some sources) concerns the same dopamine/prolactin pharmacology lineage as MIF-1, not myostatin biology. The myostatin-inhibitor branding shares the same naming-overlap pattern as MIF-1.
Current research status
No active pharmaceutical development program for MIF-2 as a myostatin inhibitor. The compound exists in grey-market peptide channels with marketing claims that are not supported by published myostatin-biology research. As with MIF-1, the historical literature on the underlying sequence concerns unrelated pharmacology.
Mechanistic rationale
Marketed as a myostatin-pathway inhibitor; the published research base for that claim is essentially absent. The underlying short-peptide sequences described in the historical MIF-2 literature concern dopamine and prolactin modulation rather than myostatin or ActRIIB pathway biology.
Available evidence
Historical pharmacology literature — Limited 1970s/1980s dopamine/prolactin research on the underlying sequence; not directly relevant to myostatin biology.[1]
Myostatin-inhibitor research base — Essentially absent. No published clinical trials or rigorous preclinical studies establishing MIF-2 as a myostatin pathway inhibitor.
Why it's interesting
MIF-2 is most useful as a paired example with MIF-1 of how grey-market peptide marketing can build a category — myostatin-inhibitor short peptides — that is largely disconnected from the published research on the underlying sequences. For users evaluating peptides in this category, the appropriate skepticism applied to MIF-1 applies equally to MIF-2.
Limitations & risks
Same limitations as MIF-1: minimal myostatin-pathway research base, grey-market supply chain with no quality assurance, marketing claims substantially outrun the underlying evidence. Anyone interested in actual myostatin-pathway inhibition should look to the antibody and receptor-blockade programs (apitegromab, bimagrumab, trevogrumab) where actual clinical data exists.
Community discussion notes
Discussed alongside MIF-1 in performance-enhancement communities. The two compounds are typically marketed and used together, with the same evidence-base limitations.
The takeaway
MIF-2 sits in the same evidentiary position as MIF-1: branded as a myostatin inhibitor in grey-market channels, supported almost entirely by marketing rather than published myostatin-pathway research. Users seeking validated myostatin-pathway therapeutics should look elsewhere; users encountering MIF-2 in vendor channels should treat the claim base with substantial skepticism.
References
- Plotnikoff NP, Kastin AJ. Pharmacological studies with a tripeptide, prolyl-leucyl-glycine amide. Arch Int Pharmacodyn Ther. 1974;211(2):211-224. https://pubmed.ncbi.nlm.nih.gov/4376908/
- Lee SJ. Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction. J Clin Invest. 2021;131(9):e148372. https://pubmed.ncbi.nlm.nih.gov/33938454/